Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Advanced Malignant Solid Tumors 3Carcinoma, Non-Small-Cell Lung 2Thymoma 1Stomach Neoplasms 1Renal Cell Cancer Metastatic 1Kidney Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Advanced Cancer 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiotherapy 6Cisplatin 6Sunitinib 5Carboplatin 5Paclitaxel 4Thymectomy 3130-nm albumin-bound paclitaxel 3selinexor 2lenvatinib 2fludarabine 2Taxes 2Robotic Surgical Procedures 2Ramucirumab 2Prednisone 2Pemetrexed 2Octreotide 2Nivolumab 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Imatinib Mesylate 2Etoposide 2Erlotinib Hydrochloride 2Doxorubicin 2Chemoradiotherapy 2Celecoxib 2zimberelimab 1vorolanib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymoma × vorolanib × Clear all
NCT03583086 2024-10-08

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
88 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡